Virginia Legislature Legalizes Recreational Cannabis, But Sales Won’t Start Until 2024
The legalization bill would allow adults over 21 to possess up to 1 ounce (28 grams) of cannabis from January 1, 2024.
How Does Cannabis Vapor Testing Work?
Cannabis vapor testing is quickly becoming the next frontier of marijuana analysis. But how does it work?
High-CBD Hemp Crops Are Mostly Marijuana, Genetic Study Finds
Hemp crops may have more in common with recreational, “drug-type” varieties of cannabis than previously thought, according to new research from the University of Minnesota.
The Risks and Rewards of Different Cannabis Separation Techniques
Alisia Ratliff, CEO of Victus Capital Ventures, explores the world of cannabis separation techniques – the good, the bad, and the expensive.
Behind the World-First Export of Jamaican Psilocybin Mushrooms
The biotech and life sciences company Mydecine Innovations Group recently announced it had completed its first commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. Technology Networks caught up with the company's chief scientific officer, Rob Roscow, to find out more.
Over Three-quarters of CBD Topicals Don’t Contain Advertised Amounts of CBD, Study Finds
Around 77 percent of tested CBD topical products don't contain the correct amount of CBD advertised on the product’s label, according to a new investigation from Leafreport.
Kaycha Labs to Open Three New Labs in Massachusetts, Nevada, and Oregon
Two of the new facilities, based in Oregon and Nevada, have been acquired by Kaycha. The other, based in Massachusetts, was built for the company.
One Month Until the Deadline, There’s Still Some Confusion Around CBD Novel Foods Applications in the UK
Regulation is incoming for the UK's CBD industry. But are companies clued up on the new requirements? Not always, say CBD analysts, and the confusing guidance may be partly to blame.
MDMA-assisted Therapy a “Promising New Treatment” for PTSD, Finds Review
The researchers found MDMA-assisted psychotherapy to have a particularly “impressive effect size” in reducing PTSD symptoms. But they say more studies will be needed before the drug can be recommended for clinical practice.
